Literature DB >> 2694315

The chemotherapy of onchocerciasis. XIII. Studies with ivermectin in onchocerciasis patients in northern Ghana, a region with long lasting vector control.

K Awadzi1, K Y Dadzie, S Kläger, H M Gilles.   

Abstract

One hundred and ninety eight patients with moderate to heavy infections with Onchocerca volvulus were randomly assigned to receive single doses of 100, 150 or 200 mcg/kg of ivermectin or matching placebo capsules. Detailed systemic, ocular and parasitological examinations were carried out at intervals over a period of one year. Nodules were excised twelve months after treatment to evaluate the effect of the treatment with ivermectin in adult O. volvulus. The three ivermectin-treated groups produced massive reductions in skin microfilariae (over 97%) with low levels being maintained over one year. The 150 and 200 mcg/kg doses were however superior to the 100 mcg/kg dose in achieving a greater reduction in skin microfilarial counts initially and in maintaining significant lower levels throughout the period of observation. There was no difference between the 150 and 200 mcg/kg doses at anytime. The three ivermectin doses were equally effective in the clearance of ocular microfilariae. The proportion of dead adult worms was very high in all treatment groups, which is effected by the successful ten years lasting vector control in northern Ghana. In spite of this superannuation of the worm population, an impact of the treatment with ivermectin on the reproductivity of the parasite could be shown. Systemic total clinical reaction was mild and was similar in the ivermectin treated groups. However, severe symptomatic postural hypotension (SSPH) was limited to patients treated with 150 or 200 mcg/kg of ivermectin. Ocular reactions were mild in all patients and no ocular deficiency occurred.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2694315

Source DB:  PubMed          Journal:  Trop Med Parasitol        ISSN: 0177-2392


  7 in total

1.  Decrease in adverse reactions after repeated ivermectin treatment in onchocerciasis.

Authors:  A Van der Lelij; A Rothova; N Klaassen-Broekema; W R Wilson; R F Barbe; J S Stilma
Journal:  Doc Ophthalmol       Date:  1990-10       Impact factor: 2.379

2.  Identifying sub-optimal responses to ivermectin in the treatment of River Blindness.

Authors:  Thomas S Churcher; Sébastien D S Pion; Mike Y Osei-Atweneboana; Roger K Prichard; Kwablah Awadzi; Michel Boussinesq; Richard C Collins; James A Whitworth; María-Gloria Basáñez
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-17       Impact factor: 11.205

Review 3.  Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis.

Authors:  K L Goa; D McTavish; S P Clissold
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

4.  Genotypic analysis of β-tubulin in Onchocerca volvulus from communities and individuals showing poor parasitological response to ivermectin treatment.

Authors:  Mike Y Osei-Atweneboana; Daniel A Boakye; Kwablah Awadzi; John O Gyapong; Roger K Prichard
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-02-12       Impact factor: 4.077

Review 5.  Drug treatment of tropical parasitic infections: recent achievements and developments.

Authors:  I Stephenson; M Wiselka
Journal:  Drugs       Date:  2000-11       Impact factor: 11.431

Review 6.  Onchocerciasis drug development: from preclinical models to humans.

Authors:  Adela Ngwewondo; Ivan Scandale; Sabine Specht
Journal:  Parasitol Res       Date:  2021-10-13       Impact factor: 2.289

7.  A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection.

Authors:  Kwablah Awadzi; Nicholas O Opoku; Simon K Attah; Janis Lazdins-Helds; Annette C Kuesel
Journal:  PLoS Negl Trop Dis       Date:  2014-06-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.